Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
National Marrow Donor Program (NMDP) and Center for International Blood and Marrow Transplant Research (CIBMTR) – Research Database for Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 12, 2020
Assessing Health Related Quality of Life in Hypersensitivity Pneumonitis
Study Status:
Open to Enrollment
Primary Investigator:
Date: August 24, 2020
Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer in 4 Weeks v. 2 Weeks (SHORTER)
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 1, 2020
Advancing Liver Therapeutic Approaches (ALTA). The ALTA Consortium Study Group for the Management of Portal Hypertension – A 5-year Longitudinal Observation Study of Patients with Cirrhosis Undergoing TIPS Placement
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 10, 2020
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 15, 2020
Hypertension, Brain Clearance, and Markers of Neurodegeneration
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 22, 2020
Reward Processing in Aging and Depression (RAD)
Study Status:
Open to Enrollment
Primary Investigator:
Date: September 23, 2020
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 2, 2020
Phase I/II Dose-Escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 8, 2020
A Multi Center Phase I study of AIC100 in Relapsed and/or Refractory Advanced Thyroid Cancer and Anaplastic Thyroid Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: October 15, 2020